30 Aug 2024
Agenda for the September 2024 PBAC Intracycle meeting
Agenda for the September 2024 PBAC Intracycle meeting
30 Aug 2024
PBAC Public Summary Documents – May 2024 meeting
PBAC Public Summary Documents – May 2024 meeting
28 Aug 2024
Publication of 12-month review of Minimum Stockholding Requirements and Excel breach notification form
Publication of 12-month review of Minimum Stockholding Requirements and Excel breach notification form
23 Aug 2024
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2024
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) – July 2024
19 Aug 2024
New PBS listing for migalastat (Galafold®) for the treatment of Fabry disease
On 1 September 2024, migalastat (Galafold®) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Fabry disease under certain circumstances.
02 Aug 2024
Xolair® (omalizumab) PBS pricing information
Xolair® (omalizumab) PBS pricing information
01 Aug 2024
Advance notice of 1 February 2025 change in Authority level for saxagliptin with dapagliflozin (Qtern® 5/10)
Advance notice of 1 February 2025 change in Authority level for saxagliptin with dapagliflozin (Qtern® 5/10)
